J&J sued over oral cancer test kit; Valeant ups size of buyback plan to $1.8B;

@FiercePharma: Piramal sold off its generics biz to Abbott. Now, founder wants to grow overseas via $1.5B in deals. Item $ABT | Follow @FiercePharma

> A company that makes an oral cancer diagnostic kit is suing Johnson & Johnson ($JNJ) for $60 million, claiming that the healthcare giant blocked its test to protect Listerine. News

> Valeant Pharmaceuticals' ($VRX) board of directors has approved a $300 million increase in its share buyback plan, bringing the total authorized to $1.8 billion. Valeant release

> Paladin Labs ($PLB) continues to lobby shareholders of Afexa Life Sciences ($FXA) on its buyout offer, saying current management hasn't followed through on growth and R&D promises. Release

> Cheap drugs that could fight heart disease, such as aspirin and generic statin drugs, are not used often enough, particularly in the developing world. Story

> The U.S. Justice Department believed Google ($GOOG) CEO Larry Page knew about improper online pharmacy ads for years, but allowed them to continue, the Wall Street Journal said. Item

> A Canadian court authorized Labopharm to call a special shareholder meeting to approve its acquisition by Paladin Labs. Report

> Afexa Life Sciences ($FXA) said interim results from a trial of its Cold-FX flu remedy in children were encouraging. Article

Biotech News

@FierceBiotech: Study: Less than 1% of cancer patients enrolled in a clinical trial. Piece Very troubling. | Follow @FierceBiotech

@JohnCFierce: 52% of hospital/pharmacy purchasing agents bought drugs from gray market vendors in past 2 years. Price gouging? Article | Follow @JohnCFierce

@RyanMFierce: I have to think Medtronic folks are scrambling in the wake of the storm created by the insulin-pump hacker's report Story $MDT | Follow @RyanMFierce

@MaureenFierce: Pfizer (finally) wins a big one with crizotinib approval for lung cancer. News | Follow @MaureenFierce

> Adimab adds Novo, Biogen Idec to roster of antibody partners. More

> Zymeworks inks $187M Merck deal on bi-specific antibodies. Report

> Roche HDL drug dalcetrapib clears a crucial safety test. Item

> Pfizer, BMS unveil mega-blockbuster data on apixaban. Details

> Pfizer (finally) wins a big one with crizotinib approval for lung cancer. Story

> FDA demands more data on Novartis's ACZ885. News

> Actelion drug flunks PhII but safety data bolsters confidence in blockbuster PhIII. Article

Biotech IT News

> FierceBiotech IT's Labor Day schedule. News

> Alzheimer's trial database finds takers in W. Florida. More

> NexDocs opens the door to VC with $10.3M funding. Report

> Case Western spinoff wins NIH grant for software. News

> China a new frontier for growing clinical tech firm. Article

> Report: Samsung to test genetic analysis service. Details

> NIH pumping $25M to link EMR info to genetic data. Story

Medical Device News

> Lantos appoints CEO, closes Series B round. More

> Aleva raises $13.8M in Series A. Article

> Medtronic sees positive results with CoreValve. Report

> FDA clears Axis-Shield assay to diagnose RA. Story

> Abbott Molecular, Pfizer get nod for drug, companion Dx. Details

> Yates to head EMD Millipore. News

And Finally... Laughter helps cardiovascular health, but anger could literally cause a heart attack. Report

Suggested Articles

An oncologist leader RBC Capital Markets interviewed expressed comfort that Trodelvy will succeed in earlier-line TNBC and in HR-positive disease.

Gilead Sciences is the latest drugmaker to settle Justice Department claims that its charity contributions were actually kickbacks.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.